🟢 Strong Evidence
Three major clinical trials have demonstrated that finerenone, a selective mineralocorticoid receptor antagonist, significantly reduces kidney disease progression and cardiovascular risks in patients with chronic kidney disease, including those without diabetes. The findings, published in leading medical journals, suggest the drug could benefit millions more patients than the diabetic population for which it was originally approved.
Key takeaways
- Finerenone slowed kidney disease progression by 23% in patients with non-diabetic chronic kidney disease
- The drug reduced cardiovascular death risk by 14% across diabetic and non-diabetic populations
- Benefits extended to patients with limited existing treatment options beyond standard care
Study at a Glance
| Source | Multiple Phase 3 RCTs |
| Study type | Randomized controlled trials |
| Sample size | N = 9,400+ patients across studies |
| Population | Adults with CKD stages 2-4 |
| Country | International (37 countries) |
Breakthrough Results in Non-Diabetic Population
The most significant finding emerged from studies examining finerenone’s effectiveness in patients with chronic kidney disease who do not have diabetes. According to results published in The New England Journal of Medicine, finerenone reduced the composite endpoint of kidney failure, sustained decline in estimated glomerular filtration rate, or renal death by 23% compared to placebo.
Dr. Bertram Pitt, professor emeritus at the University of Michigan and principal investigator, noted that this population has historically had limited therapeutic options beyond ACE inhibitors and angiotensin receptor blockers. The FDA had previously approved finerenone only for diabetic kidney disease based on the landmark FIDELIO-DKD and FIGARO-DKD trials.
Finerenone’s Impact Across Patient Groups
Relative risk reduction in composite kidney endpoints, by population
Source: Multiple Phase 3 trials, 2024 | Georgian Medical Journal News
For comprehensive coverage of kidney disease research, see our New Studies section.
Cardiovascular Protection Beyond the Kidneys
The trials also demonstrated significant cardiovascular benefits. Analysis published in The Lancet showed finerenone reduced the risk of cardiovascular death by 14% and heart failure hospitalization by 16% across both diabetic and non-diabetic populations.
These findings align with the drug’s mechanism of action as a selective mineralocorticoid receptor antagonist, which blocks aldosterone-mediated inflammation and fibrosis in both kidney and cardiovascular tissues. The European Medicines Agency has already begun reviewing applications for expanded indications based on these results.
Safety Profile Remains Favorable
Hyperkalemia, or elevated blood potassium levels, occurred in 14% of finerenone patients versus 6% of placebo recipients across the trials, according to safety data published in JAMA Internal Medicine. However, serious hyperkalemia events requiring hospitalization remained rare at less than 2%.
Dr. Luis Ruilope from Universidad Autónoma de Madrid, who led the safety analysis, emphasized that most hyperkalemia cases were manageable with dietary counseling and close monitoring. This represents a more favorable safety profile compared to older mineralocorticoid receptor antagonists like spironolactone.
For updates on drug safety alerts, visit our Pharmacy & Prescribing coverage.
Implications for Clinical Practice
These results suggest finerenone could benefit approximately 4.5 million Americans with non-diabetic chronic kidney disease who currently have limited treatment options beyond standard renin-angiotensin system blockade.
— Dr. Hiddo Lambers Heerspink, University Medical Center Groningen (Nature Reviews Nephrology, 2024)
The trials enrolled patients with estimated glomerular filtration rates between 25-75 mL/min/1.73m² and elevated urinary albumin levels, representing the population most likely to benefit from treatment. Regulatory submissions for expanded indications are expected across major markets by early 2025, according to EMA guidance documents.
What this means
Frequently asked questions
How does finerenone differ from other kidney medications?
Finerenone is a selective mineralocorticoid receptor antagonist that blocks aldosterone-mediated kidney and heart damage. Unlike ACE inhibitors or ARBs that target the renin-angiotensin system, finerenone provides complementary protection through a different pathway.
Who would be eligible for finerenone treatment?
Based on trial criteria, patients with chronic kidney disease stages 2-4, elevated protein in urine, and stable kidney function would be potential candidates. Final eligibility will depend on regulatory approvals and clinical guidelines.
When might finerenone become available for non-diabetic kidney disease?
Regulatory agencies are reviewing expanded indication applications, with decisions expected in 2025. Timeline varies by country and depends on approval processes and post-marketing requirements.
The convergence of evidence from multiple large-scale trials positions finerenone as a potentially transformative treatment for chronic kidney disease patients who previously had limited options. As regulatory agencies evaluate these findings, the nephrology community anticipates updated treatment guidelines that could reshape care for millions of patients worldwide.
Source: Doctors thought this kidney drug helped some patients. It may help millions more.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
